Lymphomas

Lymphomas

The main aim of the Lymphoma Project Group is to develop and expand scientific collaboration with other international research groups. We hope that these partnerships will lead to new clinical studies that can survive in a competitive research environment and give Swiss Cancer Institute a high level of visibility.

Ongoing Studies

EMCL-Registry

Creation of a European mantle cell lymphoma registry

SAKK 38/23 LIBERTY

Non-Hodgkin B-cell lymphoma

Recruitment completed

HOVON 127/ SAKK 37/16

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DAEPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Recruitment completed

IELSG-37

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

MorningLyte

MORNINGLYTE: international, multicenter phase III study to evaluate the efficacy and tolerability of mosunetuzumab in combination with lenalidomide compared to standard treatment in patients with previously untreated follicular lymphoma.

NX-5948-301

NX-5948-301 A Phase I study to determine the best dose(s) for the treatment of adult patients with B-cell lymphoma or leukemia who have relapsed and/or have not responded to other treatment with the investigational compound NX-5948, which degrades the enzyme Bruton's tyrosine kinase.

Recruitment completed

SAKK 38/19

SAKK 38/19 Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma

Recruitment completed

IELSG-47

MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

IELSG-48

Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)

CLL18

Comparison of three therapies in patients with previously untreated chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL)

Lymphoma project group

The group also aims to provide a platform for young clinical researchers and promote translational research in lymphoid tumors.

In case you have an interest in a specific indication within the Lymphoma group, you are kindly requested to contact the designated responsible individual for further guidance:

Indolent Non-Hodgkin Lymphoma

Noémie Lang

Vice President Project Group Lymphoma

+41 22 372 33 11 noemie.lang@hcuge.ch
Frank Stenner

President Project Group Lymphoma

+41 61 265 50 74 frank.stenner@usb.ch

Ongoing Studies

Creation of a European mantle cell lymphoma registry

Non-Hodgkin B-cell lymphoma

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DAEPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

MORNINGLYTE: international, multicenter phase III study to evaluate the efficacy and tolerability of mosunetuzumab in combination with lenalidomide compared to standard treatment in patients with previously untreated follicular lymphoma.

NX-5948-301 A Phase I study to determine the best dose(s) for the treatment of adult patients with B-cell lymphoma or leukemia who have relapsed and/or have not responded to other treatment with the investigational compound NX-5948, which degrades the enzyme Bruton's tyrosine kinase.

SAKK 38/19 Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma

MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)

Comparison of three therapies in patients with previously untreated chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL)

Lymphoma project group

Indolent Non-Hodgkin Lymphoma

Follicular lymphoma

Waldenström Macroglobulinemia

Marginal Zone Lymphoma

Lymphoplasmozytic Lymphoma

CNS Lymphomas

T-Cell Lymphomas

Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

Multiple Myeloma

Hodgkin Lymphoma

Mantel Cell Lymphoma

Translational research specialist